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Background: Collagen-binding integrins bind differentially to different types of collagen.
Results: The solution structure of integrin 1I domain in complex with a collagen-mimetic peptide was determined.
Conclusion: Integrin 1I domain binds collagen in a distinct orientation compared with 2I, but the signal transduction
mechanisms appear to be conserved.
Significance: Understanding the collagen binding specificity of integrins might enable their selective modulation in disease.
We have determined the structure of the human integrin 1I
domain bound to a triple-helical collagenpeptide. The structure
of the 1I-peptide complex was investigated using data from
NMR, small angle x-ray scattering, and size exclusion chroma-
tography that were used to generate and validate a model of the
complex using the data-driven docking program, HADDOCK
(High Ambiguity Driven Biomolecular Docking). The structure
revealed that the1I domainundergoes amajor conformational
change upon binding of the collagen peptide. This involves a
large movement in the C-terminal helix of the I domain that
has been suggested to be the mechanism by which signals are
propagated in the intact integrin receptor. The structure sug-
gests a basis for the different binding selectivity observed for the
1I and 2I domains. Mutational data identify residues that
contribute to the conformational change observed. Further-
more, small angle x-ray scattering data suggest that at low col-
lagen peptide concentrations the complex exists in equilibrium
between a 1:1 and 2:1 1I-peptide complex.
Integrins comprise a family of non-covalently associated het-
erodimeric cell surface receptors containing an  subunit and a
 subunit. They mediate interactions between individual cells
as well as interactions between cells and the extracellular
matrix (ECM).2 These receptors act as mediators that transmit
bidirectional signals across the cell membrane. In outside-in
signaling, signals are triggered by the binding of ECM ligands to
the extracellular domain of the integrin and are propagated
through the receptor to reach the intracellular domain and gen-
erate cellular responses. In contrast, inside-out signaling results
from the binding of cytosolic molecules to the cytoplasmic
domain of the integrin receptor, which can regulate the binding
affinity of the receptors for ligands in the ECM (1).
Four of the 24 integrins are characterized by their ability to
bind to collagen and are categorized as the collagen-binding
integrins. All four collagen-binding integrins contain a 1 sub-
unit that is in complex with an 1, 2, 10, or 11 subunit to
form the 11, 21, 101, and 111 receptors. These four
collagen-binding integrins vary in terms of their tissue distribu-
tion and cellular signaling pathways, but they share a common
role of mechanically supporting cell adhesion to collagen in the
ECM and maintaining tissue integrity (2). Of these, 11 and
21 are the best characterized and have been reported to play
important roles in cellular processes such as angiogenesis, the
regulation of collagen expression by fibroblasts, T-cell activa-
tion, and collagen-induced platelet aggregation (2–4). They
have also been implicated in disease processes including
inflammation as well as metastasis in certain cancers, making
them attractive therapeutic targets (4–7).
All four collagen-binding integrins contain an inserted
domain called the I domain (I), comprising 200 residues,
which is located in the extracellular region of the subunit. The
I domains contain the major binding site for ECM ligands of
these receptors, and recombinant isolated I domains recapit-
ulate many of the ligand binding properties of the intact integ-
rins (8, 9). This makes the I domains suitable models for the
study of specific interactions between integrins and ECM
ligands. All I domains assume a Rossmann fold, which is com-
posed of five parallel -strands and one antiparallel -strand
* This work was supported in part by a grant from the Monash-Nottingham
Research Fund.
Chemical shiftsofall assigned resonancesof theGLOGEN-bound1Iweredepos-
ited in BioMagResBank under accession number 18942.
The atomic coordinates and structure factors (code 2M32) have been deposited
in the Protein Data Bank (http://wwpdb.org/).
1 To whom correspondence should be addressed: Medicinal Chemistry,
Monash Institute of Pharmaceutical Sciences, 381 Royal Parade, Parkville,
Victoria 3052, Australia. Tel.: 613-99039540; Fax: 613-99039582; E-mail:
martin.scanlon@monash.edu.
2 The abbreviations used are: ECM, extracellular matrix; HADDOCK, High
Ambiguity Driven Biomolecular Docking; I, I domain; 2I, 2I domain;
MIDAS, metal ion-dependent adhesion site; O or Hyp, hydroxyproline;
HSQC, heteronuclear singlequantumcorrelation; SOFASTHMQC, selective
optimized flip angle short transient heteronuclear multiple quantum
coherence; CSP, chemical shift perturbation; TROSY, transverse relaxation-
optimized spectroscopy; AIR, ambiguous interaction restraint; SEC, size
exclusion chromatography; SAXS, small angle x-ray scattering;WAXS,wide
angle x-ray scattering.
THE JOURNAL OF BIOLOGICAL CHEMISTRY VOL. 288, NO. 52, pp. 36796–36809, December 27, 2013
© 2013 by The American Society for Biochemistry and Molecular Biology, Inc. Published in the U.S.A.
36796 JOURNAL OF BIOLOGICAL CHEMISTRY VOLUME 288•NUMBER 52•DECEMBER 27, 2013
 at UQ Library on M
arch 15, 2017
http://w
w
w
.jbc.org/
D
ow
nloaded from
 
surrounded by six-helices. TheI domain coordinates a diva-
lent metal ion at a site termed the metal ion-dependent adhe-
sion site (MIDAS), which is part of the collagen-binding site.
The metal-coordinating residues of the MIDAS are located in
three loops on one surface of the I domain (10, 11).
The four collagen-binding integrins bind differentially to dif-
ferent types of collagen. For example,11 has a higher binding
affinity for collagen type IV than for collagen type I, but 21
preferentially binds collagen type I over collagen type IV (12–
14). Synthetic peptides that mimic specific collagen sequences
and contain repeats of the amino acid motif GXX have been
used widely in the study of integrin-collagen interactions.
These peptides spontaneously self-assemble to adopt the triple-
helical conformation that is found in native collagen. As these
peptides form homotrimers, they do not recapitulate the het-
erotrimeric structure observed in some collagens. Nonetheless,
they have proved to be extremely valuable tools to probe the
binding specificity and structure of collagen-binding proteins
(15–18). Using peptides such as these, several specific recogni-
tion motifs have been identified for 11 and 21 integrins
(18–21). The recognition motifs are generally six-residue
sequences flanked on either side by several repeats of GPO (gly-
cine-proline-hydroxyproline). They include GFOGER (15),
which is found in collagen type I, as well as GLOGEN and
GROGER from collagen type III (18, 21).
A crystal structure has been reported previously for the 2I
domain (2I) in complex with a triple-helical peptide contain-
ing the GFOGER motif (22). Comparison of the liganded and
unliganded 2I structures revealed that significant conforma-
tional changes occur on binding (22). This structure provided
the first insights into the activation mechanism of collagen-
binding I domains. Themajor structural changes observed on
ligand binding include 1) a rearrangement at the MIDAS that
was caused by a change in the metal ion coordination involving
a glutamate residue from the collagen peptide (GFOGER); 2) a
10-Å downward shift of the C-terminal helix (helix 7), which
was proposed to form an interaction with the 1 subunit of the
receptor and propagate the signal toward the cytoplasmic
domain (22–26); and 3) an uncoiling of a one-turn-and-a-half
helix (C helix), which is located above theMIDAS in the unligan-
ded state. The uncoiling was proposed to open up the MIDAS to
allow the collagen-mimetic peptide to bind. Ligand binding to2I
was accompanied by the breakage of a salt bridge betweenArg288,
which is located in the C helix, and residue Glu318 from helix 7.
Loss of this salt bridge was proposed to be partly responsible for
the uncoiling of the C helix that accompanies peptide binding. A
single point mutation at Glu318 (E318W) showed increased bind-
ing affinity for collagen, suggesting the involvement of this confor-
mational change in 2I activation (27, 28).
Because of their sequence and structural homology and their
shared ability to bind to collagen, 1I and 2I domains have
been proposed to use a similar activation mechanism to trans-
mit signals. However, there have been no structures of any 1I-
peptide complexes to confirm this hypothesis. The structure of
the unliganded form of 1I reveals a salt bridge between resi-
dues Arg287 and Glu317, and the structure of 1I containing the
mutation E317A was reported in 2011 (29). The E317Amutant
showed enhanced binding affinity for collagen as had previ-
ously been observed following mutation of the similar residue
in 2I (E318W), although the structure was different from that
of 2I in complex with GFOGER. The C helix in 1I E317A
uncoiled as observed in the 2I-GFOGER complex, but the
displacement of helix 7 did not occur, and the metal ion at
the MIDAS of 1I E317A was pentacoordinated, whereas the
MIDAS in 2I-GFOGER was hexacoordinated. More recently,
analysis of the solution structure of E317A using NMR (30)
showed evidence of significant conformational change in the
mutant. In addition, the E317Amutation led to increased binding
to collagen and increased activationof the intact11 receptor. In
contrast, the mutation R287A produced less pronounced effects
on collagen binding and receptor activation, whereas a charge-
reversedmutant, R287E/E317R, displayed a phenotypemore sim-
ilar to E317A. This led the authors to propose that 1) the role of
Glu317 in stabilizing the low affinity conformation of 1I is largely
independent of the salt bridge with Arg287 and may result from
interactions with helix dipoles in the structure and 2) mutation of
Glu317 may be sufficient to result in displacement of helix 7 in
contrast to the crystal structure (29). However, the NMR data
demonstrated that the protein containing the E317A mutation
was conformationally flexible, and it is possible that the crystal
structure represents one state of E317A.
Here, we report the solution structure of human 1I domain
in complex with a collagen-mimetic peptide. The triple-helical
peptide contained aGLOGEN recognition sequence, which is a
high affinity ligand of 1I (18). The binding orientation of the
peptide is different from that observed for GFOGER binding to
2I, and a close comparison of the interfaces reveals differences
that may account for their collagen binding preferences.
Despite the difference in ligand binding orientations, the sig-
naling mechanisms appear to be conserved. GLOGEN binding
to 1I resulted in significant conformation changes including
the uncoiling of the C helix, displacement of helix 7, and break-
age of the Arg287-Glu317 salt bridge, consistent with what was
observed in 2I domain upon binding. The structure of the
complex revealed the formation of a new salt bridge between
Glu317 and Arg171 from helix 1. However, R171Amutation had
little effect on the structure of either the unliganded or the
peptide-bound state from which we infer that the Glu317-
Arg171 salt bridge is not crucial for the binding of collagen or
1I activation. In contrast, mutation R287A or E317A pro-
duced significant conformational change in the 1I domain.
Analysis of the NMR data provided strong evidence that helix 7
was displaced in both of these mutants, suggesting that the salt
bridge observed in the unliganded structure is important in
maintaining the low affinity conformation. However, the two
mutants showed different patterns of chemical shift perturba-
tions in NMR spectra for residues at the collagen-binding site,
suggesting that they have differential effects on the structure of
binding site. These differences may explain the different effects
of these mutations on the collagen binding affinity observed.
During the course of the investigation, we also identified and
characterized a dimeric complex of 1I-GLOGEN that sup-
ports the binding pose determined for the monomer. These
data together provided a more complete structural profile of
the collagen-bound 1I domain that advances our understand-
ing of signaling and specificity in collagen-binding integrins.
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EXPERIMENTAL PROCEDURES
Production of1I Domain
Uniformly 15N-labeled, 15N,13C-labeled, and 2H,15N,13C-la-
beled human1Iwas prepared as described previously (31). For
expression of unlabeled 1I, the same protocol was followed
except Luria broth (Sigma-Aldrich) was used instead of isoto-
pically labeled minimal medium, and expression was initiated
by induction with isopropyl 1-thio--D-galactopyranoside
(Astral Scientific, Australia; 1 mM) at an A600 of 0.6.
Synthesis of Collagen Peptide
A collagen peptide containing the sequence Ac-GPOGPO-
GLOGENGPOGPOGPO-NH2 was synthesized and purified as
described previously (32) except that Fmoc (N-(9-fluorenyl)met-
hoxycarbonyl)Rink-amide resin (Chem-Impex International)was
used. The peptide is referred to hereafter as GLOGEN.
Backbone Resonance Assignment
NMR experiments were conducted at 298 K on a Bruker
Avance 800 spectrometer equippedwith a cryoprobe. The sam-
ple contained 15N,13C-labeled 1I (1.2 mM) and unlabeled
GLOGEN peptide (2.4 mM) in the NMR buffer (50 mMHEPES,
pH 7.4, 50 mM NaCl, 5 mM MgCl2, and 10% 2H2O). The chem-
ical shifts were referenced according to the method described
by Wishart et al. (33) in which the 1H chemical shifts were
referenced to the water peak, whereas the 15N and 13C chemical
shifts were referenced by the 15N/1H and 13C/1H gyromagnetic
ratios. For the backbone resonance assignments, two-dimensional
1H,15N HSQC, three-dimensional HNCA, three-dimensional
HN(CO)CA, three-dimensional HNCACB, and three-dimen-
sional HNCO spectra were acquired. Except where noted other-
wise, spectra were processed using Topspin (version 3.0, Bruker-
BioSpinTM), and the analysis was carried out using SPARKY (34).
Titration ofWild-type (WT)1I with GLOGENUsing
Two-dimensional NMR
To observe GLOGEN binding to 1I, a series of two-dimen-
sional 1H,15N SOFAST HMQC (35) spectra on uniformly 15N-
labeled1I was acquiredwith stepwise addition of peptide. The
samples contained 1I (100 M) in NMR buffer. GLOGENwas
added from a stock solution (10 mM in water) to give final pep-
tide concentrations of 22.5, 45, 90, 180, and 360 M. Spectra
were recorded at 293 K on a Bruker Avance 600-MHz NMR
spectrometer equipped with a cryoprobe. Chemical shift per-
turbations (CSPs) caused by peptide binding were measured
from two-dimensional 1H,15N TROSY spectra of uniformly
2H,13C,15N-labeled1I (400M) inNMRbuffer in the presence
and absence of GLOGEN (800 M). Spectra were recorded at
293 K on a Varian INOVA 600-MHz NMR spectrometer fitted
with a cryogenically cooled probe. CSPs were derived for each
assigned residue using the following equation.
CSP 0.154 N2 H2 (Eq. 1)
Analysis of1I Mutants Using Two-dimensional NMR
1H,15N TROSY spectra on uniformly 15N-labeled R171A,
R287A, and E317A 1I mutants were acquired. The samples
contained 275 M R171A, 200 M R287A, or 100 M E317A in
NMR buffer. To observe the binding of GLOGEN, the peptide
was added to a final concentration of 560 M in the case of
R171A, 200 M in the case of E317A, or 560 M in the case of
R171A. Spectra were recorded at 293 K on a Bruker Avance
600-MHz NMR spectrometer equipped with a cryoprobe.
T1 and T2 Relaxation
T1 and T2 relaxation data were acquired for WT 1I as
described by Farrow et al. (36) at 293 K on a Varian INOVA
600-MHz NMR spectrometer equipped with a cryogenically
cooled probe. The unliganded sample contained 15N-labeled
1I (400 M). The peptide-bound sample contained 15N,13C-
labeled 1I (1.2 mM) and GLOGEN (2.4 mM). Samples were
prepared in the NMR buffer. The relaxation delay was sampled
at 0.05, 0.1, 0.2, 0.4, 0.8, 1.2, 1.6, and 2.0 s for the longitudinal
relaxation measurement and 0.01, 0.03, 0.05, 0.07, 0.09, 0.11,
0.13, and 0.15 s for the transverse relaxation measurements. A
two-dimensional heteronuclear 1H,15N NOE spectrum was
acquired with 3 s of weak irradiation at either the center of the
amide proton frequency range to generate the heteronuclear
NOE or 10,000-Hz off-resonance for the no-NOE control.
Spectra were processed using NMRPipe (37), and the signal
decay was analyzed and plotted using SPARKY (34). Theoreti-
cal T1/T2 ratios for different structural models were generated
using the program HYDRONMR (38).
Side-chain Assignments and NMR Structure Calculation
For the side-chain assignments and generation of struc-
tural restraints, three-dimensional HBHA(CBCACO)NH was
recorded on a Bruker Avance 500-MHz spectrometer fitted
with a cryoprobe, three-dimensional 1H,1HNOESY 15NHSQC
and three-dimensional 1H,1H NOESY 13C HSQC (aromatic)
experimentswere recorded on aBrukerAvance 800-MHz spec-
trometer fitted with a cryoprobe, and three-dimensional 1H,1H
NOESY 13C HSQC (aliphatic) was recorded on a Bruker
Avance 900-MHz spectrometer fitted with a cryoprobe. All
spectra were recorded at 298 K. For the NOESY spectra, the
mixing time was 60 ms, and the 13C-carrier frequency was 28
and 123.5 ppm for the aliphatic and aromatic 13C-edited
NOESY spectra, respectively. CARA (Computer-aided Reso-
nance Assignment) was used for spectral analysis. Automated
structure calculation was performed using the software pack-
age UNIO-ATNOS/CANDID (39, 40) in combination with the
torsion angle dynamics programCYANA 3.0 (41) following the
protocol described by Serrano et al. (42). Structures were cal-
culated initially in the absence of a Mg2 ion. The 20 conform-
ers with the lowest target function values were analyzed to
determine the site of Mg2 ion binding. Based on the CSP pat-
tern of 1I on Mg2 ion binding and the crystal structure of
2I-collagen peptide complex, the Mg2 was assigned to coor-
dinate with residues Ser152, Ser154, and Thr220 in our 1I struc-
tures. Subsequently, a Mg2 ion was introduced to the struc-
tures using a “pseudo-link” consisting of 30 “pseudo-residues”
extending from the C terminus. Structures were recalculated in
the presence of the Mg2 ion using UNIO-ATNOS/CANDID
as described above with the addition of backbone torsion angle
restraints generated by the programTALOS (43). In addition,
Structural Analysis of Integrin1I Domain-Collagen Complex
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hydrogen bond restraints (two per bond) were added in regions
of canonical secondary structure where a unique hydrogen
bond donor-acceptor pair was evident from structural conver-
gence. The 20 structures having the lowest target function with
Mg2 bound were then refined using Cartesian dynamics in
CNS (44) after removal of the pseudo-link to produce the final
structures. The 20 lowest energy conformers with no NOE vio-
lations0.25 Å, no bond violations0.05 Å, and no improper
or dihedral angle violations 5° were chosen to represent the
solution structure of liganded 1I.
HADDOCKDocking
The docking of collagen peptide to 1I was performed using
the data-driven docking program HADDOCK (45, 46).
1I Template—The 20 lowest energy structures of 1I in its
liganded state were used as the protein input templates.
Restraints that were used in the original structure calculation,
i.e. NOEs, H-bonds, and dihedral angle restraints, were
included in the docking process to constrain the protein in its
liganded conformation. Regions of the protein with low T1/T2
ratios, low values of the heteronuclear NOE, and low angular
order (S2) values predicted fromchemical shiftswere allowed to
be fully flexible during docking. HADDOCK requires a set of
ambiguous interaction restraints (AIRs) at the binding inter-
face that are divided into “active” and “passive” categories
where active residues are those directly implicated in binding
from experimental data and passive residues are their near neigh-
bors. Residues on 1I for which active AIRs were generated were
selected based on their havingNMRCSPs0.5 ppm and a loss of
NMR signal intensity70% upon titration of1I with GLOGEN.
Exclusion criteria were residues in regions of the protein that
showed fast time scale dynamics in the heteronuclearNOEexper-
iment and residues that were not solvent-accessible.
GLOGEN Peptide Template—For the peptide input tem-
plate, the initial model was obtained by computationally mod-
ifying an available crystal structure of a triple-helical collagen
peptide (ProteinDataBank code 1Q7D) (47). The peptide in the
crystal structure contains a GFOGER recognition motif, which
was converted to GLOGEN using the mutagenesis function in
PyMOL (The PyMOLMolecular Graphics System, Version 1.3,
Schro¨dinger, LLC). Although the peptide is a homotrimer, each
of the strands is in a unique chemical environment, referred to
as the “leading,” “middle,” and “trailing” strands, as viewed from
their N termini. To make sure that the triple-helical structure
wasmaintained during the docking, hydrogen bonds present in
the crystal structure were included as input restraints. AIRs
were also generated for the peptide based on previous studies
that showed the essentiality of the glutamate residue in the
GLOGEN motif. It was known that one of the three glutamate
residues is responsible for coordinating with the metal ion at
the 1I, but it was unclear whether any one of the glutamate
residues in the trimeric peptide model is preferred over the
other two. To predict whether 1I has a preference for coordi-
nating to any one of the three strands, a preliminary docking
was conducted with an ambiguous distance restraint set such
that any of the three glutamate residues of the triple-helical
peptide may coordinate with the magnesium ion. Residues
within 8 Å of a glutamate were defined as active, and residues
between 8 and 12Å from the glutamate were defined as passive.
This length matches the diameter of the binding interface of
1I and is likely to cover all potential residues on the peptide
that could make direct interactions with 1I. Based on the low-
est energy cluster arising from the preliminary dock, a unique
peptide interface was defined, and seven active and eight
passive residues were selected as the “optimized” peptide
AIRs.The active residues comprisedHyp10,Gly11, andAsn13 from
the leading strand and Hyp110, Gly111, Asn113, and Gly114 from
the middle strand. The passive residues comprised Gly8, Leu9
from the leading strand; Gly108, Leu109, Pro115, and Hyp116
from themiddle strand; and Pro215 and Pro216 from the trailing
strand. The leading strand glutamate-magnesium ion interac-
tion was assigned as an unambiguous distance restraint as pre-
vious studies have confirmed its essentiality for binding (10).
The docking process included a rigid body energy minimization
step, which produced 1000 structures. The best 200 structures
were subjected to a semiflexible simulated annealing step and then
a final low temperature flexible refinement in explicit waters.
Mutagenesis
Mutagenesiswasperformedusing theQuikChange IImutagen-
esis kit (Agilent Technologies) according to the manufacturer’s
instructions. The pET28a plasmid containing the WT 1I insert
was used as the template with the following primers used to gen-
erate the R171A and E317A mutations: R171A: forward, 5-
AGCTTTTTTAAATGACCTTCTTGAAGCAATGGATAT-
TGGTCCTAAACAGACA-3; reverse, 5-TGTCTGTTTAGG-
ACCAATATCCATTGCTTCAAGAAGGTCATTTAAAAAA-
GCT-3; E317A: forward, 5-AAGCATTTCTTCAATGTCTCT-
GATGCCTTGGCTCTAGTCACCATTGTTAAA-3; reverse,
5-TTTAACAATGGTGACTAGAGCCAAGGCATCAGAGA-
CATTGAAGAAATGCTT-3. The presence of mutations was
verified by DNA sequencing. For the R287A mutant, a synthetic
gene encoding 1I with the mutation in the pET28a plasmid was
ordered from DNA2.0. The mutants were expressed in 15N-la-
beled minimal medium following the same protocol used for the
WT 1I integrin.
Analytical Size Exclusion Chromatography (SEC)
Analytical SECwas carried out using a Superdex 75HR10/30
column (GE Healthcare) with a bed volume of 23.6 ml on an
A¨KTATM purifier protein chromatography system. Samples
(100 l) containing 1I (10 M) with or without GLOGEN (20
M) were applied to the column equilibrated with 50 mM
HEPES buffer, pH 7.4, 50 mM NaCl, and 5 mM MgCl2. A flow
rate of 0.7 ml/min was maintained, and the elution was moni-
tored by continuousmeasurement of UV absorbance at 280 nm
(A280). The runs were conducted at room temperature.
SEC-SAXS
All SAXS data were acquired at the Australian Synchrotron
SAXS/WAXS beamline and the data collection and scattering-
derived parameters are described in Table 2 according to the
recommendations of the International Union of Crystallogra-
phy Commission on Small-Angle Scattering (48). The SAXS
experiments were set up in line with gel filtration chromatog-
raphy as described by Gunn et al. (49). Samples (50l) contain-
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ing unlabeled 1I (372 M) with and without GLOGEN (744
M)were injected onto a 2.4-ml gel filtration column (Superdex
75 PC 3.2/30, GE Healthcare) equilibrated with 50 mM HEPES
buffer, pH 7.4, 50 mM NaCl, and 5 mM MgCl2. The runs were
carried out at room temperature, and the flow rate was 0.2
ml/min. SAXS15ID software was used to analyze the detector
images as averages of 10 sequential 2-s exposures, and the data
were converted to individual I(q) SAXS profiles. The scattering
intensity (I) was collected over the momentum transfer vector
(q) range of 0.011–0.620 Å1 (q	 (4sin)/	where (2) is the
scattering angle and 	 is the x-ray wavelength, which was
1.0332 Å). For the final data sets, 367 and 357 data points were
extracted within the range of 0.01–0.5 and 0.02–0.5 Å1 from
the original unliganded and GLOGEN-bound 1I data sets,
respectively. The SAXS profiles were analyzed using the
ATSAS program suite (50). The radius of gyration (Rg) was esti-
mated using Guinier analysis using AUTORG. The maximum
dimension of the scattering particles was estimated according
to the pair distance vector distribution functions,P(r), using the
programAUTOGNOM.The volume andmass of the scattering
particleswere estimated usingAUTOPOROD, and theab initio
shapes of the scattering molecules were estimated using
DAMMIF. The fittedmodels of the dimeric complex were con-
structed using PyMOL. The templatemonomeric complexes of
the1I-GLOGENHADDOCKstructure and the2I-GFOGER
crystal structure (22) were first duplicated. The two structures
were aligned based on the six-residue recognition motif
GLOGEN or GFOGER on different strands of the triple-helical
peptides. Theoretical SAXS profiles of the models were gener-
ated and fitted to the experimental SAXS curve using CRYSOL
(51). The statistical analysis of goodness of fit was performed as
described by Mills et al. (52). The program OLIGOMER (53)
was used to compute the proportions ofmonomer and dimer in
both 1I and the 1I-GLOGEN complex.
RESULTS
GLOGEN Binding to 1I Observed by NMR—The sequence
of the peptide used in the study contained the integrin recogni-
tion sequence GLOGEN flanked by five GPO repeats. Its ability
to self-assemble into the collagen-like triple-helical confor-
mation was confirmed using circular dichroism (data not
shown). TheGLOGENmotif is themost potent ligand for11
among the fibrillar collagen sequences, and it inhibits the bind-
ing of 11 to collagen type IV with an IC50 of 3 M (21).
Comparison of two-dimensional 1H,15N TROSY spectra of the
1I domain in the presence and absence of the GLOGEN pep-
tide revealed extensive CSPs upon addition of excess peptide
(Fig. 1). Gradual titration of 1I with the peptide revealed that
at a lowGLOGEN:1I ratio (
1:1) the two-dimensional 1H,15N
SOFAST HMQC spectra of 1I exhibited severe line broaden-
ing for most peaks in the spectrum (Fig. 1C). The intensity of
the peaks increased as the peptide concentration exceeded that
of 1I, and at a GLOGEN:1I ratio of3:1, most of the signals
were recovered (Fig. 1D). Similar broadening has previously
been reported upon titration of the 2I domain with a peptide
containing theGFOGER recognitionmotif (54). Such broadening
FIGURE 1.HSQC spectra of the titration of1IwithGLOGENpeptide.A, overlay of the 1H,15N TROSY of unliganded1I (red) and a 1:2 complex of1I bound
to GLOGEN (black) showing significant chemical shift perturbations. The samples contained 2H,15N,13C-labeled 1I (400 M) in the presence and absence of
GLOGEN (800M). The spectrawere acquired at 600MHz and 293 K. B–D, 1H,15N SOFASTHMQC spectra of 1H,15N-labeled1I (100M)with noGLOGEN (B) and
GLOGEN:1I at a ratio of 1:1 (C) and 3:1 (D). NMR spectra were acquired at 800MHz and 293 K. The spectral quality declined during the early stage of GLOGEN
titration but was gradually recovered as excess peptide was titrated into the system.
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of NMR resonances is often the result of intermediate time scale
chemical exchange. However, as the homotrimeric collagen-mi-
metic peptides potentially have three I domain binding sites, the
formation of a larger oligomeric complex at lowpeptide:1I ratios
is a possible explanation for the loss of signal intensity.
T1/T2 Analysis of the Stoichiometry of the Complex—The
oligomeric state of the 1I-GLOGEN complex was assessed
using NMR by measuring the heteronuclear 1H,15N T1/T2
relaxation ratios for 1I domain in the absence and presence of
a 2-fold excess of GLOGEN. The experimental data were com-
pared with theoretical data generated using HYDRONMR (38)
for the isolated 1I domain (Protein Data Bank code 1QCY
(55)), isolated2I domain (ProteinDataBank code 1AOX (56)),
the monomeric GFOGER-2I complex (Protein Data Bank
code 1DZI (22)), and a model that consisted of two I domains
bound to one triple-helical peptide (Fig. 2). Themodel of the 2:1
complex was generatedmanually by docking a second 2Imol-
ecule onto the structure of the GFOGER-2I complex. The
theoretical T1/T2 ratios for the 2:1 complex were significantly
higher than the rest of the models due to its size and shape. The
fluctuation in the T1/T2 values is related to the orientation of the
amide N–H bond vectors with respect to the principle axis frame
of the rotational diffusion tensor in the calculation. This kind of
variation is typical for elongated ellipsoidal proteins such as that of
the 2:1 complex. The global T1/T2 ratio measured for the 1I-
GLOGENcomplex is in good agreementwith the theoretical data
derived for the monomeric complex and is consistent with the
formation of a 1:1 complex between 1I domain and the triple-
helical GLOGEN at high GLOGEN:1I domain ratios.
Structure of the 1I Domain Bound to GLOGEN—The struc-
ture of 1I domain bound to GLOGENwas determined using a
sample containing 15N,13C-labeled 1I (1.2 mM) in the pres-
ence of Mg2 (5 mM) and unlabeled GLOGEN (2.4 mM). The
pattern of CSPs observed upon addition of Mg2 to 1I was
consistentwith the position of themetal ion in the crystal struc-
ture of GFOGER-2I complex (31). The coordination of Mg2
in our structure was therefore assumed to be similar to the 2I
complex structure. An ensemble of 20 conformers representing
the structure of 1I bound to GLOGEN (from a total of 40
structures calculated) is shown in Fig. 3. Structural statistics for
the ensemble are shown in Table 1. The structure assumes a
typical Rossmann fold consisting of five parallel -strands and
one antiparallel-strand surrounded by six-helices. Compar-
ison of the lowest energy model with the unliganded structure
of 1I (Fig. 4) shows that the central -sheet core remains sim-
FIGURE 3. The solution structure 1I bound to GLOGEN. A, stereoviews of
the backbone of the 20 lowest energy structures of 1I with the Mg2 ion
shown as a gray sphere. B, a schematic of the lowest energy structure in the
ensemblewith theMg2 shownas agray sphere. The residues that coordinate
the Mg2 ion, Ser152, Ser154, and Thr220, are highlighted asmagenta sticks.
TABLE 1
NMR and refinement statistics for 20 structures of the 1I domain
bound to GLOGEN
Non-redundant NOE distance restraints
Total 2444
Intraresidue (i	 j) 623
Sequential (i j	 1) 748
Medium range (1
 i j
 4) 504
Long range (5) 569
Dihedral angle constraints 864
Residual NOE violations
Number0.1 Å 39 7
Maximum (Å) 0.15 0.01
Residual dihedral angle violations
Number2.5° 1 1
Maximum (°) 3.04 1.64
Pairwise root mean standard deviation
Backbone atoms (residues 4–142, 153–187) (Å) 0.76 0.10
Heavy atoms (residues 4–142, 153–187) (Å) 1.52 0.16
Ramachandran plot statistics
Most favored region (%) 81.9
Additionally allowed regions (%) 15.9
Generously allowed regions (%) 2.0
Disallowed regions (%) 0.1
FIGURE 2. Theoretical and experimental T1/T2 ratios for I domain-pep-
tide complexes. The theoretical T1/T2 of the unliganded 1I (red) matches
with the experimentally determined T1/T2 of the unliganded 1I sample
(blue). The T1/T2 of the GLOGEN-bound 1I (cyan) was determined with a
sample containing a 2-fold excess of GLOGEN. The experimental data are
consistent with theoretical data for a 1:1 GLOGEN-1I complex (gold). The
theoretical T1/T2 ratios for the 2:1 complex of 1I-GLOGEN (black) are signif-
icantlydifferent, suggesting that the1:1 complexdominatesunder theexper-
imental conditions. Residues 283–293 and the C terminus of GLOGEN-bound
1I show a marked decrease in T1/T2, suggesting that these are flexible
regions of the protein.
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ilar with an root mean square deviation on the C of 1.1 Å.
Major conformational differences were identified in two
regions. The first region is the C helix of the unliganded state
that becomes completely unfolded upon peptide binding.
Unwinding of the short C helix results in extending the E-6
loop (residues 281–292). Very few NOEs could be assigned in
the E-6 loop in NOESY spectra of the complex. The
TALOS-predicted angular order (S2) values (43) showed a
clear decrease in the predicted order in the E-6 loop of 1I
upon binding to GLOGEN (Fig. 4A). This is supported by com-
parison of the 1H,15N heteronuclear NOE for 1I unliganded
and in complex with GLOGEN that revealed a decrease upon
peptide binding, consistent with increased dynamics in this
region in the bound state (Fig. 4B). These findings are consis-
tent with the lower precision observed in this region of the
structure of 1I (Fig. 3A).
The second region undergoingmajor conformational change
is the C-terminal helix (helix 7), which is displaced downward
by 12 Å upon GLOGEN binding relative to its position in the
unliganded structure. In the unliganded state, helix 7 is linked
to the C helix by a salt bridge between Arg287 and Arg317. This
salt bridge is broken in the complex with GLOGEN. In its new
position in the complex, Glu317 is in a position from where it
may form a salt bridge with Arg171 from helix 1 (Fig. 4F). To
investigate the importance of the salt bridges in regulating the
conformational changes, single point mutants with R171A,
R287A, and E317A substitutions were studied (Fig. 5).
The 1H,15NTROSY spectrumof the R171Amutant (275M)
in the absence and presence of GLOGEN (500 M) showed a
high degree of similarity to the spectrum of the unliganded and
peptide-bound states of WT 1I, respectively. Chemical shift
changes were only observed for residues located in close prox-
imity to themutation site in each case (Fig. 5,A andB), suggest-
ing that themutation had little impact on the structure of either
the unliganded or peptide-bound state of 1I.
In contrast, the 1H,15N TROSY spectrum of R287A (200M)
in the absence of GLOGEN showed substantial differences
from the spectrum of the unliganded WT 1I. Comparison of
the spectrum with the GLOGEN-bound WT 1I, however,
showed a much higher degree of similarity (Fig. 5, C and D). In
particular, a strong peak from the spectrum of the unliganded
R287A coincides with the peak corresponding to the C-termi-
nal residue, Ile331, in the GLOGEN-bound WT 1I (Fig. 5G).
The chemical shift and intensity of this peak suggest that this
FIGURE 4. Effects ofGLOGENbindingon1I.A, TALOS-predicted S2 value
for the unliganded (red) and GLOGEN-bound (black) 1I based on the NMR
chemical shifts. S2, the angular order parameter, describes the rigidity of a
residue as a measure of its backbone conformational entropy. It ranges
between 0 for a completely disordered residue and 1 for a rigid residue. Sig-
nificant drops at theE-6 loop (uncoiled fromC helix) and at the C terminus
in the bound state indicate a gain in flexibility in these regions of 1I upon
GLOGEN binding. B, 1H,15N NOE measurements for the unliganded (red) and
GLOGEN-bound1I (black). The low values for residues in theE-6 loop and
at the C terminus are consistent with increased flexibility in the presence of
GLOGEN. C, percentage of signal intensity loss in the 1H,15N TROSY spectrum
as a consequence of peptide binding. Residues with cross-peaks that lost
more than 70% intensity are highlighted in red. D, weighted chemical shift
perturbations measured in the TROSY spectra highlighted regions (high-
lighted with gray bars across the other panels) that were most significantly
influenced by peptide binding. Regions with the largest CSPs include the
three MIDAS loops, E-6 loop, and helix 7, which is distant from the MIDAS
but for which a 12-Å downward displacement was observed in the structure.
E and F, aligned structures with these regions highlighted for the unliganded
(red; ProteinData Bank code 1QCY) andGLOGEN-bound (black)1I domain. E
shows a zoomed image of the C helix, which is uncoiled in the liganded struc-
ture. The spheres represent the Mg2 ions. In F, the salt bridge formed
between residue Glu317 and Arg287 in the unliganded (red) or Arg171 in the
liganded (black) states is indicated as a black dotted line.
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FIGURE5.NMRanalysis of1Imutants.Overlaid spectra of 1H,15N-labeledWT (red) andR171A (blue)1I (A) andWT1I (black) andR171A (magenta)1I (B) both in
thepresenceofGLOGENareshown.Thesimilarityof theWTandR171Aspectra inboththeirunligandedandGLOGEN-boundstatessuggests that theR171Amutation
had littleeffectonpeptidebinding.C, unligandedWT(red) andR287A (blue)1I.D,WT1IwithGLOGEN(black) andunligandedR287A1I (blue). Thespectrumof the
unligandedR287Amutantshowedagreaterdegreeofsimilarity tothepeptide-boundstateofWT1I, suggestingthattheunboundstateof theR287Amutantadopts
a conformation that ismore similar to the activated state of theWT1I. E, unligandedWT (red) and E317A (blue)1I. F, WT1I with GLOGEN (black) and unliganded
E317A1I (blue). The spectrumof theunligandedE317Awas alsomore similar to the spectrumof thepeptide-bound state ofWT1I, suggesting that the E317Aalso
adopts a similar conformation.G andH, zoomed regions of the TROSY spectra highlighting residue Ile331 in unligandedWT1I (red), GLOGEN-boundWT1I (black),
and unliganded R287A (blue) (G) or E317A (blue) (H). NMR spectrawere acquired at 800MHz and 293 K.
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cross-peak in the spectrum of the R287A mutant also repre-
sents the C-terminal residue, implying that helix 7 is displaced
in the R287A mutant in the absence of peptide. Addition of
GLOGEN (400 M) to R287A induced relatively minor chemi-
cal shift changes, and the spectrumalso resembles the spectrum
of the GLOGEN-bound WT 1I. With the aid of the 15N,1H
assignments of the GLOGEN-bound WT 1I, residues that
were more severely perturbed by the R287A mutation in the
bound state were identified. Themajority of perturbed residues
are located in close proximity either to the site ofmutation or to
residues within or adjacent to the MIDAS (Fig. 6).
As was the case with R287A, the 1H,15N TROSY spectrum of
E317A in the absence of GLOGEN displayed significant differ-
ences from the spectrum of unligandedWT 1I. The spectrum
appeared to be more similar to the GLOGEN-bound state of
WT 1I (Fig. 5, E and F). The spectrum of E317A also contains
a strong peak at a chemical shift that is coincident with the
C-terminal residue (Ile331) in theGLOGEN-bound spectrumof
WT 1I, suggesting that helix 7 in E317A is displaced (Fig. 5H).
Addition of GLOGEN (400 M) to E317A resulted in relatively
minor changes to the spectrum. However, the pattern of per-
turbations relative toWT 1I was different from that observed
with R287A. Fewer perturbations were observed for residues
adjacent to the MIDAS in the spectrum of E317A. In contrast,
the majority of the perturbed residues were located in helix 1,
E-6 (the uncoiled C helix), and F sheet (Fig. 6).
Mapping the Binding Interface—The CSPs and chemical
exchange broadening that were observed in the two-dimen-
sional 1H,15N TROSY spectrum of WT 1I upon GLOGEN
binding were assessed to map the binding interface of the com-
plex. CSPs and chemical exchange broadening are observed for
residues that undergo a change in their chemical environment
upon binding. This can be caused both by direct interaction
with the ligand and indirect effects such as those due to confor-
mational change. The analysis revealed that 22 residues lost
more than 70% of their signal intensity on peptide binding.
These residues were mostly located in the three MIDAS loops,
loop E-6, and helix 6. CSPs on the other hand mapped both
to the same regions and to residues in helix 7 (Fig. 4, C and D).
Structure of the 1I-GLOGEN Complex—A structure of the
1I-GLOGEN complex was generated using the data-driven
docking programHADDOCK (45, 46) (Protein Data Bank code
2M32). Based on the selection criteria described above, residues
in helix 7 were excluded from the definition of the binding
interface as they showedno broadening, and it was inferred that
the CSPs were due to the observed conformational change in
this region rather than a direct interaction with GLOGEN. In
addition, residues 281–292 from the E-6 loop were excluded
from the binding interface as they showed fast time scale
dynamics in the heteronuclear NOE experiment and were
therefore deemed to be disordered in the bound state. The res-
idues of 1I defined as active for the HADDOCK calculation
comprised the surface-exposed residues with CSP0.5 ppm as
well as residues with a loss of signal intensity 70%, namely
Ser154, Ile155, Tyr156, Arg218, Gln219, Glu255, and His257. Only
Asn153 satisfied the criteria for being a passive residue. These
AIRs were used as input for the HADDOCK calculation. No
intermolecular NOEs were included in the HADDOCK calcu-
lations. Analysis of the 200 final structures using their
HADDOCK score (45, 46) produced a cluster of 10 structures, all
of which fell within the 20 best scoring structures. This cluster
was selected to represent the structure of triple-helical
GLOGEN peptide bound to 1I (Fig. 7). The lowest energy
structure of the 10 was selected to best represent the model of
the complex. It shows the peptide binding along a “trench”
above the MIDAS (Fig. 7C). Consistent with the 2I-GFOGER
complex crystal structure (22), the 1I molecule binds exclu-
sively to the leading (cyan) and middle (orange) strands as
shown in Fig. 7F. The trailing strand (green) does not make any
interaction with 1I. The binding orientation of the peptide,
however, is different from the 2I crystal structure in which
GFOGER sits along the edge of the trench (Fig. 7, compare C
and D) (22). A more detailed discussion and comparison of the
two structures is presented below.
Analysis of theComplex at LowGLOGEN:1I Ratios—Poten-
tial causes of the broadening observed in the 1H,15N TROSY
spectrum of 1I at lower peptide concentrations were investi-
gated using analytical SEC and SAXS. Analysis of the SEC elu-
tion profile of a sample containing 1I and GLOGEN peptide
revealed the presence of two distinct peaks. The first of these
eluted at a volume similar to unliganded 1I (11.62 ml),
whereas the second, which was inferred to correspond to the
1I-peptide complex, eluted considerably earlier (10.02 ml)
(Fig. 8). The1.5-ml shorter elution volume suggested that the
molecular weight of the complex species wasmuch higher than
that of the unliganded state. Comparison of the elution volume
with other proteins with different molecular weight on the
same column3 suggested that this peak corresponds to a species
that is much bigger than the expected 1:1 GLOGEN-bound 1I
species (molecular mass, 27.4 kDa).
Synchrotron SAXS data were acquired for 1I in the absence
and presence of GLOGEN (Fig. 9 and Table 2). The SAXS
experiments were set up in line with SEC. The sample contain-
ing the mixture of 1I and GLOGEN eluted earlier than the
unliganded 1I sample, indicating a larger species in the mix-
3 The typical elution time of albumin and ovalbumin from a gel filtration col-
umn (Superdex 75 HR 10/30 column, GE Healthcare) was published by
European Molecular Biology Laboratory (EMBL) on the website www.
embl.de/pepcore/pepcore_services/protein_purification/chromatography/
superdex75HR10-30.
FIGURE 6. Chemical shift perturbations observed in R287A and E317A.
Schematic representationsof thepeptide-boundstateof1I highlighting the
residues for which chemical shift perturbations were observed between the
spectrumofGLOGEN-boundWT1I andR287A (red) (A) or E317A (blue) (B) are
shown. Arg287 and Glu317 are shown in stick representation.
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ture. Porod analysis of the scattering data indicated that the
estimated molecular mass of 1I-GLOGEN complex was
40.7 0.5 kDa, whereas that of the unliganded 1I was 19.2
0.2 kDa. Although the SAXS-derived parameters such asRg and
volume were stable across much of the peak (varying by less
than 2%) and consistent with a complex containing two 1I
molecules, the resolution of the small bed volume column used
was insufficient to cleanly separate the larger species from later
eluting species such as 1:1 1I-GLOGEN complex or free 1I.
Indeed, single value decomposition analysis using SvdPlot in
PRIMUS (53) of the entire elution consisting of 11 SAXS data
sets from across the peak suggested a mixture of at least three
species.
The Rg values, distance distribution functions P(r), and cal-
culated maximum dimension (Dmax) (Fig. 9) also suggested the
presence of a GLOGEN-bound 1I species that was consider-
ably bigger and more elongated than the unliganded 1I or a
putative 1:1 1I-GLOGEN complex. Therefore, we postulated
that a complex composed of two 1I molecules bound to a
single homotrimeric peptidemayhave formed.The1I domain
can in theory bind to any two of the three strands of the peptide
to form three different combinations of two 1I domains
bound to one GLOGEN triple helix (2:1 complex). These three
models were built using the lowest energy HADDOCK model
as a template. Two of the three combinations showed signifi-
cant steric clashes and were excluded from further investiga-
tion (data not shown). Although the SAXSdatawere likely to be
from a mixture, the Porod mass estimate suggested that the
volume fraction of any smaller species was reasonably small
(10%). Therefore,ab initio reconstruction from the SAXSwas
performed, and an average-filtered shape envelope was gener-
ated. Although the normalized special discrepancy of the shape
envelopes was low (0.711 0.067), a relatively high reduced 2
statistic (v2) of 2.13  0.02 was noted from the DAMMIF
reconstructions. This appears to be largely due to the detector
count statistics of the synchrotron SAXS data underestimating
the true uncertainty but may also reflect the inability of a single
shape to adequately describe the scattering from the mixture.
FIGURE 7. HADDOCK-calculated structure of the 1I-GLOGEN complex. A, schematic representation of a cluster of 10 conformers of the 1I-GLOGEN
complex. TheMg2 ion is shownas agray sphere. The three strands of the triple-helical collagenpeptide, referred to as the leading,middle, and trailing strands,
are shown in cyan, orange, and green, respectively. B and C, the lowest energy conformer in the cluster of the 1I-GLOGEN complex. GLOGEN binds across a
surface trench in the1I.D, crystal structure of the2I-GFOGER peptide complex (Protein Data Bank code 1DZI) with the three peptide strands of the collagen
peptide shown in yellow. The orientation of 2I in Dwas aligned with the 1I in C for clear comparison of the binding orientation of the two peptides. In 2I,
the peptide bound along the edge of the surface trench. E and F, close-up of the MIDAS of the lowest energy conformer of the 1I-GLOGEN complex. The
middle strand contains the glutamate residue that coordinates with the Mg2. Residues that are involved in polar interactions are shown as sticks. Only the
middle and leading strands showed specific interactionswith1I. Note that the asparagine from the leading strand is accommodated in a surface pocket next
to the Mg2 ion (E).
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The HADDOCK-derived 2:1 model shows good shape corre-
spondence with the SAXS envelope (Fig. 9). Despite the overall
shape similarity between the HADDOCK-derived model and
average-filtered shape (normalized special discrepancy of 0.94),
the fit of the theoretical scattering profile from thismodel to the
SAXS data generated using CRYSOL (51) was relatively poor
with a v2 of 5.3. There are several plausible reasons why this is
the case. Again, the issues of detector count statistics and the
presence of other species (e.g. free peptide, unbound 1I, and
monomeric complex)would have contributed to the high value.
In addition, the GPO repeats at the tails of the GLOGEN pep-
tides from the HADDOCK model fit particularly poorly in the
envelope, suggesting that they may be flexible. To address the
issue of mixed species, OLIGOMER (53) was used to esti-
mate the scattering contribution of the different species
present. The best fit obtained was for 88% 2:1 complex, 7% 1:1
complex, and 5% free peptide. The v2 for this volume fraction
composition was 3.1, which represents a statistically significant
improvement in the goodness of fit (F 	 1.71; PF 
 3  107)
over the 2:1 complex alone or any other combination of species
tested. It seems likely that further improvements in goodness of
fit could be obtained by considering flexibility either in the
GLOGEN peptide tails or in the E-6 loop and helix 7 and/or
some variability in the relative1I domain orientation in the 2:1
complex. Nonetheless, in relative terms, the HADDOCK-de-
rived 2:1model provides a statistically significant improvement
in fit compared with any other 2:1 model tested including the
corresponding 2:1 complex based on the GFOGER-2I crystal
structure, suggesting that the difference in peptide binding ori-
entation observed between the1I and2I complex is genuine.
DISCUSSION
We have determined the structure of the 1I domain bound
to a triple-helical peptide that is a mimic of its natural ligand
FIGURE 8. Elution profile of 1I in the absence (red) and presence (black)
of GLOGEN on an analytical size exclusion column. In the red trace, the
peak at 11.68 ml represents unliganded 1I, whereas the peak at 10.02 ml
observed in the presence of GLOGEN corresponds to a much larger species.
Comparison of the elution volume with albumin (67 kDa) and ovalbumin (44
kDa) revealed that the complex is likely to have amolecularmass greater than
the 27 kDa expected for a 1:1 GLOGEN-1I complex.
FIGURE 9. SAXS model of 1I and GLOGEN-1I complex. A, plot of SAXS
diffraction intensity versus q for the samples containing 1I alone (red) and
1I with GLOGEN (black). Error bars indicate1 S.D. B, Porod analysis on the
data acquired for the samples containing 1I alone (red) and 1I with
GLOGEN (black). C, alignment of the model of the dimeric 1I-GLOGEN com-
plex with the ab initio SAXS envelope. The model consists of two 1I mole-
cules (red) and one triple-helical peptide (black). The two 1I molecules were
orientated so that theMg2 ions at theMIDAS are coordinated by glutamate
residues from twoof the three peptide strands. The SAXS envelope (shown in
gray grid) shows a slightly bent but elongated shape, which fits well with the
dimeric model even though the envelope is unable to fit the two ends of the
peptide. AU, arbitrary units.
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collagen. The structure reveals that binding is accompanied by
movement of theMIDAS loops aswell asmajor conformational
changes in the C helix (residues Leu282–Gly288), which became
uncoiled in the bound state, and a displacement of the C-termi-
nal helix (helix 7), whichmoved by12Å relative to its position
in the unliganded state. These structural rearrangements are
consistent with those observed in the structure of the 2I upon
binding to GFOGER. Further validation of the current struc-
ture is provided by a recent analysis of the dynamics of 1I in
complex with collagen type IV using hydrogen-deuterium
exchangemass spectroscopy (57). The study provided evidence
of increased conformationalmobility in the region between res-
idues 283 and 290, corresponding to loop E-6 (including the
uncoiled C helix), as well as the region between residues 318
and 332, which corresponds to helix 7. The intervening ele-
ments between the two regions also showed moderate confor-
mational changes as comparedwith the unliganded state of1I.
This is confirmed by our NMR results where T1/T2 relaxation
(Fig. 2), heteronuclear NOE experiments (Fig. 4B), the S2 values
predicted from chemical shifts (Fig. 4A), and the NMR struc-
tures themselves (Fig. 3A) all indicate conformational changes
and increased backbone dynamics in these regions of 1I upon
GLOGEN binding.
The current structure provides a basis to investigate the
mechanisms by which collagen binding, which is accompanied
by subtle changes close to the MIDAS, leads to the large con-
formational changes that are thought to propagate signaling. In
the peptide-bound state, the MIDAS rearrangement is associ-
ated with a change in the conformation of the side chain of
Tyr285, which rotates away from its original position and
exposes an accessible binding site for collagen or collagen pep-
tides. The C helix unfolds, and the resulting E-6 loop is
highly flexible as indicated by the NMR relaxation data and
bends away from the collagen peptide so that it is not involved
directly in the binding interaction. Peptide binding also causes
a kink in helix 6 (residues Glu293–Ala303), which results in a
small displacement (4.5Å) in the adjacent short-strand (F)
and the large downwardmovement of helix 7 (residues Glu317–
Glu329). This downward movement of helix 7 has been postu-
lated to be key for integrin signaling andmediates communica-
tion of the 1I domain with the I domain of the integrin 
subunit (58). A new salt bridge between Glu317 and Arg171 was
observed in the bound state, linking the displaced helix 7 to
helix 1. To test whether this salt bridge is essential for stabiliz-
ing the active state of 1I, we made the R171A mutation and
examined its effect upon the conformation of1I in its unligan-
ded and liganded states using 1H,15N TROSY NMR. However,
the similarity of the WT and R171A spectra in both their unli-
ganded and GLOGEN-bound states suggests that the salt
bridge is not crucial for collagen binding or for 1I activation.
In contrast, either the R287A or E317A mutation resulted in
large perturbations being observed in the 1H,15N TROSY spec-
tra of the unliganded proteins relative to the spectrum of WT
1I. In the case of E317A, the perturbations we observed are
consistent with a previous study (30). In that case, the authors
proposed that E317A represents an activated conformation of
1I as the mutation of Glu317 enhanced signaling as shown by
increased ERK activation and down-regulation of collagen syn-
thesis. It was suggested that the E317A mutation led to a down-
ward displacement of helix 7 not due to disruption of the salt
bridge with Arg287 but as a result of the loss of a favorable mono-
pole-helical dipole interaction between the negative charge of
Glu317 and the partial positive charge of the helix 7 dipole (30). In
support of this interpretation, the R287A mutation in the same
study did not result in similar activation of the intact receptor.
Our results do not support this interpretation. We have
acquired 1H,15NTROSY for bothmutants, andwith the benefit
of full assignments for WT 1I, the spectra provide strong evi-
dence that helix 7 is displaced in both cases. However, it is also
apparent from analysis of the spectra that the two mutations
have different effects on residues at the collagen-binding site of
1I (Fig. 6). Thus, we believe that the differences observed in
the previous study may have resulted from themutations alter-
ing the collagen binding affinity of the two proteins.
The HADDOCK model of 1I in complex with GLOGEN
shows that the peptide binds along a surface trench above the
MIDAS on 1I (Fig. 7C). In contrast, in the structure of 2I in
complex with GFOGER, the peptide binds at the edge of a
similar trench (Fig. 7D) (22). Our SAXS data support the
HADDOCK model of 1I-GLOGEN, whereas a model based
on the 2I-GFOGER crystal structure showed a very poor fit to
the SAXS envelope. Analysis of the binding interfaces provides
some indications as to the structural basis of these differences.
First, the asparagine residues of the leading strand GLOGEN
motif sits in an acidic pocket formedbyAsp253 andGly254 of1I
(Fig. 7E). Replacing the asparaginewith a bulkier arginine could
potentially create a steric clash in that pocket, which may
TABLE 2
SAXS data collection and scattering-derived parameters
† Reported for the averaged SAXS data where Porod volume estimates from suc-
cessive blocks of 5 2-s exposures did not vary by more than 1.5% from the
mean value.
‡ Calculated for two 1 monomers bound to a GLOGEN triple helix.
N/A, not applicable.
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account for the observation thatGLOGENbindsmore potently
to the 1I domain than GFOGER. Second, comparison of the
sequences indicates a change where residue Ala218 in 1I cor-
responds to Asp219 in 2I. In the structure of the 2I-GFOGER
complex, Asp219 is located at the edge of the trench and forms a
salt bridge with one of the arginine residues in the GFOGER
motif. The change to Ala218 in 1I precludes the formation of a
similar interaction in the1I complex, whichmay contribute to
both the peptide binding preferences observed for the two I
domains (15, 21) and the subtle change in binding orientation of
the peptides between the two complexes.
Homotrimeric helical peptides have been used widely as col-
lagen mimetics and represent excellent tools to study the bind-
ing of collagen on collagen receptors. They have been especially
helpful in the process of identifying specific recognition motifs
for collagen-binding integrins (17). For such homotrimeric
peptides, there are potentially three equivalent binding sites
that may support binding to integrin I domains. Therefore, in
a case where the individual strands in the peptide are in the
appropriate orientation for I binding and no steric hindrance
is present, more than one strand in the same peptide should in
theory be able to bind to an individual I molecule simultane-
ously. Herein, our size exclusion and SAXS results provide evi-
dence for the existence of a dimeric complex for 1I bound to
GLOGEN. To our knowledge, this is the first report describing
a dimeric complex between an I domain and a triple-helical
collagen peptide, but we believe that the SEC result presented
by Lambert et al. (54) may also demonstrate the same phenom-
enon in 2I upon peptide binding, although it was explained as
an artifact resulting from the elution of the rigid, elongated
helical peptide. In the case of 1I bound to GLOGEN, T1/T2
NMRrelaxationdata confirmed the formationof a1:1monomeric
complex at higher peptide concentrations. Based on these obser-
vations, we propose that in the presence ofGLOGEN1I adopts a
dynamic equilibriumbetweenanunliganded state, a dimeric com-
plex state ((1I)2-GLOGEN), and a monomeric complex state
(1I-GLOGEN). Under conditions where the GLOGEN con-
centration is low with respect to the 1I, the dimeric complex
state dominates, but as the peptide:1I ratio increases, the equi-
librium position shifts to favor the formation of monomer.
However, as collagen is abundant in the ECM and I domains
recognize heterotrimeric collagen sequences, we believe that
this dimeric complex is unlikely to dominate in vivo and may
not be biologically significant.
CONCLUSION
The structure of 1I bound to GLOGEN suggests that the
mechanism of signaling in this receptor is similar to that reported
previously for2I. However, the structure suggests that themode
of peptide binding to 1I is subtly different from that observed
with 2I. The current structure provides a rationale for the
observed differences in binding specificity between 1I and 2I.
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